WO2023166348 - TREATMENT OF SYSTEMIC SCLEROSIS AND IDIOPATHIC PULMONARY FIBROSIS
National phase entry:
Publication Number
WO/2023/166348
Publication Date
07.09.2023
International Application No.
PCT/IB2023/000142
International Filing Date
02.03.2023
Title **
[English]
TREATMENT OF SYSTEMIC SCLEROSIS AND IDIOPATHIC PULMONARY FIBROSIS
[French]
TRAITEMENT DE LA SCLÉROSE SYSTÉMIQUE ET DE LA FIBROSE PULMONAIRE IDIOPATHIQUE
Applicants **
HORIZON THERAPEUTICS IRELAND DAC
Inventors
ALI, Farah Naseer
PELOSO, Paul
Priority Data
63/315,793
02.03.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3547 | |
| EPO | Filing, Examination, Granting | 25991 | |
| Japan | Filing, Examination, Granting | 3077 | |
| South Korea | Filing, Examination, Granting | 3956 | |
| USA | Filing, Examination, Granting | 10190 |
Total:
46,761
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Described herein are uses of crystalline forms of 2-(4-methoxy-3 -(3- methylphenethoxy)benzamido)-2,3-dihydro-1H-indene-2-carboxylic acid in the treatment of diseases or conditions that would benefit by administration with an LPA1 receptor antagonist compound.[French]
L'invention concerne des utilisations de formes cristallines de l'acide 2-(4-méthoxy-3-(3-méthylphénéthoxy)benzamido)-2,3-dihydro-1H-indène-2-carboxylique dans le traitement de maladies ou de pathologies qui pourraient tirer partie d'une administration d'un composé antagoniste de récepteur LPA1.